We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Biopharma Credit Plc | LSE:BPCR | London | Ordinary Share | GB00BDGKMY29 | ORD USD0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.006 | 0.68% | 0.884 | 0.878 | 0.884 | 0.884 | 0.876 | 0.876 | 1,644,747 | 16:28:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 135.74M | 108.45M | 0.0833 | 8.38 | 909.27M |
TIDMBPCR
RNS Number : 1342T
BioPharma Credit PLC
15 July 2020
BioPharma Credit plc
(the "Company")
TRANSACTION IN OWN SHARES
BioPharma Credit PLC (the "Company") announces that today it has purchased the following number of its ordinary shares of US$0.01 each on the London Stock Exchange through J.P. Morgan Securities plc.
Ordinary Shares:
Date of purchase: 15 July 2020
Number of ordinary shares purchased: 22,100
Lowest price per share: $0.994
Highest price per share: $0.996
Trading venue: London Stock Exchange
Aggregate volume per date per trading venue: 22,100
Weighted average price per day per trading venue: $0.9954
The Company intends to hold the purchased shares in treasury.
Following the above transaction, the Company holds 59,694 of its ordinary shares in treasury and has 1,373,872,373 ordinary shares in issue (excluding treasury shares). Therefore, the total number of voting rights in the Company is 1,373,872,373. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries
BioPharma Credit plc
via Link Company Matters Limited
Company Secretary
+44 (0)1392 477 500
J.P. Morgan Cazenove
+44 (0)20 7742 4000
William Simmonds
Oliver Kenyon
Buchanan
+44 (0)20 7466 5000 / biopharmacredit@buchanan.uk.com
David Rydell
Mark Court
Jamie Hooper
Henry Wilson
Notes to Editors
BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.
LEI: 213800AV55PYXAS7SY24
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
POSQELFFBDLFBBQ
(END) Dow Jones Newswires
July 15, 2020 12:30 ET (16:30 GMT)
1 Year Biopharma Credit Chart |
1 Month Biopharma Credit Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions